Stockhub

Editing Oncolytics Biotech Inc.

Revision as of 18:03, 30 July 2022 by Chris (talk | contribs) (Created page with "Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab,...")
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)

Warning: You are editing an out-of-date revision of this page. If you publish it, any changes made since this revision will be lost.

Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Stockhub:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)
Retrieved from β€˜https://stockhub.co/research/Oncolytics_Biotech_Inc.’